Release issued 29th September 2006

Labtec´s licensee ratiopharm started marketing in Canada a transdermal patch containing fentanyl for treatment of strong chronic pain, which is generic to J&J´s blockbuster Durogesic®. The patch is 1/3 smaller than the originator´s product and is the first generic fentanyl patch to be approved for marketing in Canada.

Last month ratiopharm Canada launched "ratio-FENTANYL Matrix System", a product generic to Johnson&Johnson´s Durogesic®, which in 2004 generated global revenues of over 2 billion US$. The product is the first generic fentanyl patch to be approved in Canada and was developed by Germany- based Labtec GmbH who licensed it to ratiopharm for Europe and Canada. Besides Canada, the product is already approved in Germany, Austria and The Netherlands. ratiopharm is expecting approval for all other countries of their territory within the next months. Outside Europe and Canada, Labtec has licensed the product for USA, Australia, Israel and Turkey to leading national companies.

The patch uses Labtec´s innovative matrix technology making it the smallest fentanyl patch on the market. Because of its small size the product is more convenient for patients who suffer from strong chronic pain and have to wear the patch for 3 days before replacing it with a new one.

Labtec is now actively seeking to license the product to Latin America, Africa, Near East, South Asia and East Asia/Pacific. Labtec GmbH (www.labtec-pharma.com) is a leading drug delivery company specialised on development of matrix-type transdermal and topical patches as well as fast dissolving oral films (Rapidfilms).

ratiopharm (www.ratiopharm.ca) is 3rd among Canadian generic drug companies. It employs 400 people in its Mirabel and Mississauga facilities and boasts annual sales approaching $300 million.

(26th November 2008) tesa AG Acquires Labtec GmbH

(4th August 2008) Ondansetron RapidFilm™ licensed to BioAlliance Pharma for Europe

(29th January 2008) APR Applied Pharma Research s.a. ("APR") and Labtec GmbH ("Labtec") Announce the Successful Completion of the Pilot Bioequivalence Study of Their Donepezil RapidFilm

(15th January 2008) Successful completion of Pivotal Bioequivalence study for Ondansetron RapidFilm

(25th April 2007) Labtec's next generation pain patch successful in clinical studies